Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors

  • ID: 2293296
  • Report
  • 67 Pages
  • La Merie Publishing
1 of 4

FEATURED COMPANIES

  • Alopexx Oncology
  • Intas Pharmaceuticals
  • Mentrik Biotech
  • Oncobiologics
  • PlantForm
  • Spectrum Pharmaceuticals
  • MORE
The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world’s commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication.

The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets.

The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alopexx Oncology
  • Intas Pharmaceuticals
  • Mentrik Biotech
  • Oncobiologics
  • PlantForm
  • Spectrum Pharmaceuticals
  • MORE
1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors

Marketed CD20 Antibodies & Sales
- Rituxan/MabThera Pipeline & Sales
- Arzerra Pipeline & Sales
- Gazyva Pipeline & Sales
- Bexxar & Zevalin Pipeline & Sales

Biosuperior CD20 Antibodies

Biosimilar CD20 Antibodies
- Rituxan/MabThera (rituximab) Biosimilars
- Arzerra (ofatumumab) Biosimilars

2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Actavis (Watson Pharmaceuticals)
- Alopexx Oncology
- Amgen
- Aprogen
- Competitor Analysis
- Innovent Biologics
- Intas Pharmaceuticals
- Lentigen
- LG Life Sciences
- Libbs Farmaceutica
- Mabxience
- Mentrik Biotech
- Merck
- Molecular Templates
- Natco Pharma
- Nichi-Iko Pharmaceutical
- Oncobiologics
- PanGenerika
- PanPharmaceuticals USA
- Pfizer
- PharmaPraxis
- PlantForm
- Probiomed
- rEVO Biologics
- Roche
- Sandoz (Novartis)
- Shanghai CP Guojian Pharmaceutical Co
- Shanghai Henliu Biopharmaceuticals
- Spectrum Pharmaceuticals
- STADA Arzneimittel 68
- TG Therapeutics
- Therapeutics Protein International (TPI)
- TRION Pharma
- Vaccinex
- Valor Biotherapeutics
- Viropro
- Zhejiang Huahai Pharmaceutical Co
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll